{
  "resourceType": "ValueSet",
  "id": "oncology-OncotypeDxDCISRiskScoreInterpretationVS",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>BC OncotypeDxDCISRiskScoreInterpretationVS ValueSet</b></p>\n<p>Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score</p>\n</div>"
  },
  "url": "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-OncotypeDxDCISRiskScoreInterpretationVS",
  "identifier": [
    {
      "system": "http://hl7.org/fhir/us/breastcancer",
      "value": "oncology.OncotypeDxDCISRiskScoreInterpretationVS"
    }
  ],
  "name": "OncotypeDxDCISRiskScoreInterpretationVS",
  "title": "BC OncotypeDxDCISRiskScoreInterpretationVS ValueSet",
  "status": "draft",
  "publisher": "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "date": "2018-05-02",
  "description": "Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score",
  "compose": {
    "include": [
      {
        "system": "http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS",
        "concept": [
          {
            "code": "low_risk",
            "display": "Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."
          },
          {
            "code": "intermediate_risk",
            "display": "Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. Itâ€™s unclear whether the benefits of chemotherapy outweigh the risks of side effects."
          },
          {
            "code": "high_risk",
            "display": "Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."
          }
        ]
      }
    ]
  }
}